These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 26287490)

  • 41. Nationwide surveillance study of vancomycin intermediate Staphylococcus aureus strains in Korean hospitals from 2001 to 2006.
    Chung G; Cha J; Han S; Jang H; Lee K; Yoo J; Yoo J; Kim H; Eun S; Kim B; Park O; Lee Ys
    J Microbiol Biotechnol; 2010 Mar; 20(3):637-42. PubMed ID: 20372039
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Genotype-specific prevalence of heterogeneous vancomycin-intermediate Staphylococcus aureus in Asian countries.
    Chung DR; Lee C; Kang YR; Baek JY; Kim SH; Ha YE; Kang CI; Peck KR; Lee NY; Song JH
    Int J Antimicrob Agents; 2015 Sep; 46(3):338-41. PubMed ID: 25982914
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Screening for Intermediately Vancomycin-Susceptible and Vancomycin-Heteroresistant Staphylococcus aureus by Use of Vancomycin-Supplemented Brain Heart Infusion Agar Biplates: Defining Growth Interpretation Criteria Based on Gold Standard Confirmation.
    Khatib R; Riederer K; Sharma M; Shemes S; Iyer SP; Szpunar S
    J Clin Microbiol; 2015 Nov; 53(11):3543-6. PubMed ID: 26311860
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Emergence of vancomycin-intermediate Staphylococcus aureus from predominant methicillin-resistant S. aureus clones in a Korean hospital.
    Cha HY; Kim HO; Jin JS; Lee JC
    J Microbiol; 2010 Aug; 48(4):533-5. PubMed ID: 20799097
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Investigation of the VISA and hVISA Presence in Methicillin-Resistant Staphylococcus aureus Isolates by Various Methods].
    Uçar Ş; Duman Y; Tanrıverdi ES; Tekerekoğlu MS; Otlu B
    Mikrobiyol Bul; 2022 Oct; 56(4):593-605. PubMed ID: 36458707
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prospective comparison of the clinical impacts of heterogeneous vancomycin-intermediate methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-susceptible MRSA.
    Horne KC; Howden BP; Grabsch EA; Graham M; Ward PB; Xie S; Mayall BC; Johnson PD; Grayson ML
    Antimicrob Agents Chemother; 2009 Aug; 53(8):3447-52. PubMed ID: 19506056
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Detection of Staphylococcus aureus isolates with heterogeneous intermediate-level resistance to vancomycin in the United States.
    Richter SS; Satola SW; Crispell EK; Heilmann KP; Dohrn CL; Riahi F; Costello AJ; Diekema DJ; Doern GV
    J Clin Microbiol; 2011 Dec; 49(12):4203-7. PubMed ID: 21976769
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Molecular features of heterogeneous vancomycin-intermediate Staphylococcus aureus strains isolated from bacteremic patients.
    Maor Y; Lago L; Zlotkin A; Nitzan Y; Belausov N; Ben-David D; Keller N; Rahav G
    BMC Microbiol; 2009 Sep; 9():189. PubMed ID: 19732456
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Emergence of vancomycin-intermediate and -resistant Staphylococcus aureus among methicillin-resistant S. aureus isolated from clinical specimens in the northwest of Iran.
    Ghahremani M; Jazani NH; Sharifi Y
    J Glob Antimicrob Resist; 2018 Sep; 14():4-9. PubMed ID: 29454049
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China.
    Sun W; Chen H; Liu Y; Zhao C; Nichols WW; Chen M; Zhang J; Ma Y; Wang H
    Antimicrob Agents Chemother; 2009 Sep; 53(9):3642-9. PubMed ID: 19546358
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clonal dissemination of meticillin-resistant and vancomycin-intermediate Staphylococcus aureus in a Taiwanese hospital.
    Hsueh PR; Lee SY; Perng CL; Chang TY; Lu JJ
    Int J Antimicrob Agents; 2010 Oct; 36(4):307-12. PubMed ID: 20685086
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Genomic insights on heterogeneous resistance to vancomycin and teicoplanin in Methicillin-resistant Staphylococcus aureus: A first report from South India.
    Bakthavatchalam YD; Babu P; Munusamy E; Dwarakanathan HT; Rupali P; Zervos M; John Victor P; Veeraraghavan B
    PLoS One; 2019; 14(12):e0227009. PubMed ID: 31887179
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Vancomycin MIC plus heteroresistance and outcome of methicillin-resistant Staphylococcus aureus bacteremia: trends over 11 years.
    Musta AC; Riederer K; Shemes S; Chase P; Jose J; Johnson LB; Khatib R
    J Clin Microbiol; 2009 Jun; 47(6):1640-4. PubMed ID: 19369444
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [The incidence and risk factors for heterogeneous vancomycin intermediate Staphylococcus aureus].
    Feng NN; Wang Q; Song YL; He LX; Zhou CM; Xie HM; Li HY
    Zhonghua Nei Ke Za Zhi; 2013 Apr; 52(4):318-22. PubMed ID: 23925360
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The evolution of vancomycin intermediate Staphylococcus aureus (VISA) and heterogenous-VISA.
    Howden BP; Peleg AY; Stinear TP
    Infect Genet Evol; 2014 Jan; 21():575-82. PubMed ID: 23567819
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Vancomycin-intermediate Staphylococcus aureus selected during vancomycin therapy of experimental endocarditis are not detected by culture-based diagnostic procedures and persist after treatment arrest.
    Moreillon P; Bizzini A; Giddey M; Vouillamoz J; Entenza JM
    J Antimicrob Chemother; 2012 Mar; 67(3):652-60. PubMed ID: 22167243
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Detection of heterogeneous vancomycin intermediate resistance in MRSA isolates from Latin America.
    Castro BE; Berrio M; Vargas ML; Carvajal LP; Millan LV; Rios R; Hernandez AK; Rincon S; Cubides P; Forero E; Dinh A; Seas C; Munita JM; Arias CA; Reyes J; Diaz L
    J Antimicrob Chemother; 2020 Sep; 75(9):2424-2431. PubMed ID: 32562543
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Phenotypic characteristics and comparative proteomics of Staphylococcus aureus strains with different vancomycin-resistance levels.
    Sirichoat A; Lulitanond A; Kanlaya R; Tavichakorntrakool R; Chanawong A; Wongthong S; Thongboonkerd V
    Diagn Microbiol Infect Dis; 2016 Dec; 86(4):340-344. PubMed ID: 27717648
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Vancomycin and daptomycin minimum inhibitory concentration distribution and occurrence of heteroresistance among methicillin-resistant Staphylococcus aureus blood isolates in Turkey.
    Sancak B; Yagci S; Gür D; Gülay Z; Ogunc D; Söyletir G; Yalcin AN; Dündar DO; Topçu AW; Aksit F; Usluer G; Ozakin C; Akalin H; Hayran M; Korten V
    BMC Infect Dis; 2013 Dec; 13():583. PubMed ID: 24325260
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Daptomycin non-susceptibility in vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous-VISA (hVISA): implications for therapy after vancomycin treatment failure.
    Kelley PG; Gao W; Ward PB; Howden BP
    J Antimicrob Chemother; 2011 May; 66(5):1057-60. PubMed ID: 21393156
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.